CLV IntelligenceReimbursement Policy Monitoring

Alert detail

FDA Approval: MEZOFY (ARIPIPRAZOLE) — Type 3 - New Dosage Form

Policy ID: FDA-NDA211448Specialty: NeurologyAdded: 8/6/2026Effective: April 15, 2025federal register
Low

What changed

Oral aripiprazole film routes to Part D; verify NDC and formulary.

Who’s affected: Neurology billing teams · Effective: April 15, 2025

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

View subscription plansCreate a free account

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Neurology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Neurology audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Neurology— the week’s changes and deadlines, delivered to your inbox. No account required.

FDA Approval: MEZOFY (ARIPIPRAZOLE) — Type 3 - New Dosage Form